Donna Ucci - CorMedix Senior Quality
| CRMD Stock | USD 9.96 0.37 3.58% |
Executive
Donna Ucci is Senior Quality of CorMedix
| Address | 300 Connell Drive, Berkeley Heights, NJ, United States, 07922 |
| Phone | 908 517 9500 |
| Web | https://www.cormedix.com |
CorMedix Management Efficiency
The company has return on total asset (ROA) of (0.3769) % which means that it has lost $0.3769 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6504) %, meaning that it created substantial loss on money invested by shareholders. CorMedix's management efficiency ratios could be used to measure how well CorMedix manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -0.59. In addition to that, Return On Capital Employed is expected to decline to -0.73. At present, CorMedix's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 108.2 K, whereas Other Current Assets are forecasted to decline to about 725 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Allison Nance | Lyra Therapeutics | N/A | |
| Naomi Eichenbaum | Travere Therapeutics | N/A | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Philippe Sauvage | Nuvation Bio | 47 | |
| Danka Radosavljevic | Eton Pharmaceuticals | N/A | |
| Margaux Bennett | Kronos Bio | N/A | |
| Brendan Eckelman | Inhibrx | 45 | |
| Barbara JD | Kronos Bio | 65 | |
| FACS FACS | Eledon Pharmaceuticals | N/A | |
| Ellen Cavaleri | Lyra Therapeutics | N/A | |
| Marie Rossi | Precigen | N/A | |
| Michael Alfieri | Aldeyra | 59 | |
| Rafael MD | Aptose Biosciences | 52 | |
| Christian JD | Gossamer Bio | 57 | |
| MBA III | Celcuity LLC | 63 | |
| Paul Bullock | Replimune Group | N/A | |
| Josep Garcia | Inhibrx | N/A | |
| William Rote | Travere Therapeutics | 61 | |
| John Bishop | Lyra Therapeutics | 62 | |
| Robert MD | Lyra Therapeutics | N/A | |
| Brent Eilefson | Celcuity LLC | N/A | |
Management Performance
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.38 |
CorMedix Leadership Team
Elected by the shareholders, the CorMedix's board of directors comprises two types of representatives: CorMedix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CorMedix. The board's role is to monitor CorMedix's management team and ensure that shareholders' interests are well served. CorMedix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CorMedix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph MBA, CEO Director | ||
| Donna Ucci, Senior Quality | ||
| Tushar Mukherjee, Senior Operations | ||
| Phoebe Esq, Gen EVP | ||
| Elizabeth BA, Executive Affairs | ||
| Erin Mistry, Executive Officer | ||
| Kaufman Esq, Chief VP | ||
| Matthew MD, Executive CFO |
CorMedix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CorMedix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (0.29) % | ||||
| Current Valuation | 558.87 M | ||||
| Shares Outstanding | 60.68 M | ||||
| Shares Owned By Insiders | 0.97 % | ||||
| Shares Owned By Institutions | 31.64 % | ||||
| Number Of Shares Shorted | 6.28 M | ||||
| Price To Earning | (0.88) X | ||||
| Price To Book | 10.29 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CorMedix is a strong investment it is important to analyze CorMedix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CorMedix's future performance. For an informed investment choice regarding CorMedix Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CorMedix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CorMedix. If investors know CorMedix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CorMedix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.80) | Revenue Per Share 0.212 | Quarterly Revenue Growth (0.47) | Return On Assets (0.38) | Return On Equity (0.65) |
The market value of CorMedix is measured differently than its book value, which is the value of CorMedix that is recorded on the company's balance sheet. Investors also form their own opinion of CorMedix's value that differs from its market value or its book value, called intrinsic value, which is CorMedix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CorMedix's market value can be influenced by many factors that don't directly affect CorMedix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CorMedix's value and its price as these two are different measures arrived at by different means. Investors typically determine if CorMedix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CorMedix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.